ReviewInnovation (Cambridge (Mass.))2021
Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review.
Review in Innovation (Cambridge (Mass.)), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 61 citations in OpenAlex.
- Cross-genus analysis reveals architecturally programmed sgRNA synthesis patterns in coronaviruses.Molecular systems biology · 2026Article
- Compressive pangenomics using mutation-annotated networks.Nature genetics · 2026Article
- Revived ancient viruses from deep-sea ecosystems are biothreats by triggering gut dysbiosis.mBio · 2025Article
- Scalable method for exploring phylogenetic placement uncertainty with custom visualizations usingiMeta · 2025Article
- Protein structure prediction via deep learning: an in-depth review.Frontiers in pharmacology · 2025Review
- Prediction of drug target interaction based on under sampling strategy and random forest algorithm.PloS one · 2025Article
- Landscape of human organoids: Ideal model in clinics and research.Innovation (Cambridge (Mass.)) · 2024Review
- Identification of biomarkers and pathways for the SARS-CoV-2 infections in obstructive sleep apnea patients based on machine learning and proteomic analysis.BMC pulmonary medicine · 2024Article
- Nanosponge: A promising and intriguing strategy in medical and pharmaceutical Science.Heliyon · 2024Review
- Anomaly Detection Models for SARS-CoV-2 Surveillance Based on GenomeMicroorganisms · 2023Article
- Emvirus: An embedding-based neural framework for human-virus protein-protein interactions prediction.Biosafety and health · 2023Article
- Revealing the roles of TLR7, a nucleic acid sensor for COVID-19 in pan-cancer.Biosafety and health · 2023Article
- Recent development of surface-enhanced Raman scattering for biosensing.Journal of nanobiotechnology · 2023Review
- Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies.Science China. Life sciences · 2023Review
- SARS-CoV-2 Covid-19 Infection During Pregnancy and Differential DNA Methylation in Human Cord Blood Cells From Term Neonates.Epigenetics insights · 2023Article
- Editorial: Innovations in surgical oncology.Frontiers in oncology · 2023Article
- The Outbreak of Acute Primary Angle-Closure Cases During the COVID-19 Omicron Variant Pandemic at a Tertiary Eye Center in Shanghai.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- An implementation of a hybrid method based on machine learning to identify biomarkers in the Covid-19 diagnosis using DNA sequences.Chemometrics and intelligent laboratory systems : an international journal sponsored by the Chemometrics Society · 2022Article
- Omicron B.1.1.529 subvariant: Brief evidence and future prospects.Annals of medicine and surgery (2012) · 2022Article
- Nanosponges: An overlooked promising strategy to combat SARS-CoV-2.Drug discovery today · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has spread globally to over 200 countries with more than 40 million confirmed cases and one million deaths as of November 1, 2020. The SARS-CoV-2 virus, leading to COVID-19, shows extremely high rates of infectivity and replication, and can result in pneumonia, acute respiratory distress, or even mortality. SARS-CoV-2 has been found to continue to rapidly evolve, with several genomic variants emerging in different regions throughout the world. In addition, despite intensive study of the spike protein, its origin, and molecular mechanisms in mediating host invasion are still only partially resolved. Finally, the repertoire of drugs for COVID-19 treatment is still limited, with several candidates still under clinical trial and no effective therapeutic yet reported. Although vaccines based on either DNA/mRNA or protein have been deployed, their efficacy against emerging variants requires ongoing study, with multivalent vaccines supplanting the first-generation vaccines due to their low efficacy against new strains. Here, we provide a systematic review of studies on the epidemiology, immunological pathogenesis, molecular mechanisms, and structural biology, as well as approaches for drug or vaccine development for SARS-CoV-2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.